Company Profile
Nanobiotix Stock Price, News & Catalysts
- Ticker:
- NBTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- France and listed in the U
Stock performance
43.68 USD (-3.77%)
Close
Last updated: August 20, 2026
1.86B USD
Market cap
Why the stock is moving
As of Aug 20, 2026, NBTX closed down 3.77% at $43.68. No new same-company headline was identified in the current news window.
Company overview
Business overview
Nanobiotix is a radiotherapy and oncology company focused on nanoparticle-enabled cancer treatment. Its platform is built around improving how radiation interacts with tumors.
Geographic Base and Sector Classification
Headquartered in France and listed in the U.S. as an ADR, Nanobiotix has a global oncology-biotech profile.
Business Model Characteristics
The business depends on clinical data, regulatory progress, and the ability to translate nanoparticle science into cancer value.
Position Within the Biotechnology Landscape
Nanobiotix is a catalyst-driven oncology name whose stock reacts strongly to development and partnership updates.
Future catalysts
- Nanobiotix’s catalysts are its radioenhancer platform and any oncology update that shows the technology can improve local control without unacceptable toxicity. The market will care about whether the platform continues to look clinically relevant.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Nanobiotix (NBTX)?
Nanobiotix (NBTX) most recently closed at 43.68 USD, a -3.77% move versus the previous session.
What is the market cap of Nanobiotix (NBTX)?
Nanobiotix currently has a market capitalization of 1.86B USD on BioPharmSignal.
What does Nanobiotix do?
Nanobiotix is a radiotherapy and oncology company focused on nanoparticle-enabled cancer treatment. Its platform is built around improving how radiation interacts with tumors.
On which exchange is NBTX stock listed?
Nanobiotix (NBTX) is associated with NASDAQ, France and listed in the U, Biopharma.
What is Nanobiotix?
Nanobiotix’s catalysts are its radioenhancer platform and any oncology update that shows the technology can improve local control without unacceptable toxicity.
Which conditions is Nanobiotix targeting with Nanobiotix?
Nanobiotix is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Nanobiotix describe recent progress with Nanobiotix?
Nanobiotix’s catalysts are its radioenhancer platform and any oncology update that shows the technology can improve local control without unacceptable toxicity.
What future catalysts are investors watching for Nanobiotix?
Nanobiotix’s catalysts are its radioenhancer platform and any oncology update that shows the technology can improve local control without unacceptable toxicity. The market will care about whether the platform continues to look clinically relevant.